SPRY Stock Analysis: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$8.30
0.19 (2.34%)
▲
5d:
-3.04%
30d:
-8.19%
90d:
-28.76%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
SPRY is down 4.3% this week, but smart money is accumulating calls. Top strike: $10 2026-05-15 with 818 OI. Call ratio: 100% View Scanner →
Strength: 7.2/10
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SPRY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: SPRY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $8.30, which is considered slightly low relative to its 30-day fair value range of $8.05 to $9.11.
Technical Outlook: Technically, SPRY is showing sideways momentum. Immediate support is located at $7.20, while resistance sits at $8.70.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.00 (+225.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SPRY is showing sideways momentum. Immediate support is located at $7.20, while resistance sits at $8.70.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.00 (+225.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$8.05 -
$9.11
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 225.3% below Wall St target ($27.00)
Fair Price Analysis
30-Day Fair Range
$8.05 -
$9.11
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.20
Resistance Level
$8.70
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.64
Wall Street Target
$27.00
(+225.3%)
Revenue Growth (YoY)
-67.6%
Profit Margin
-203.3%
Share & Embed Analysis
Last updated: April 02, 2026 11:02 PM ET
Data refreshes hourly during market hours. Next update: 12:02 AM
Data refreshes hourly during market hours. Next update: 12:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Dorsey
SELL
21828 shares
2025-11-13
Justin Chakma
SELL
166380 shares
2025-11-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 50 HOLD |
